Navigation Links
American Oriental Bioengineering Reports First Quarter 2010 Financial Results
Date:5/10/2010

p;D centre in Beijing.

Net income attributable to controlling interest for the first quarter of 2010 was $3.1 million, compared to $7.2 million in the prior year period. The Company's net income attributable to controlling interest was $0.04 per diluted share, compared to $0.10 per diluted share in the same period of 2009.

Balance Sheet

As of March 31, 2010, the Company had $99.0 million in cash and cash equivalents, including restricted portions, and generated approximately $5.8 million of operating cash flow during the first quarter of 2010. Working capital was $136.9 million as of March 31, 2010, reflecting an increase of 4.6% from $130.9 million as of December 31, 2009.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are very satisfied with our performance in the first quarter, despite the challenging global economic environment and the changing Chinese regulatory environment. During the past quarter, we continued to invest heavily in R&D, which consumed 5% of total revenue, in order to upgrade our existing products and develop new proprietary products to lay a solid foundation for AOBO's near term and long term growth. Meanwhile, we continued to fortify our market position, strengthen our presence in rural areas, and diversify our business operations through cost control, advertising campaigns, and sales network expansion. We are confident that we will achieve initial
'/>"/>

SOURCE American Oriental Bioengineering, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress
2. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
3. American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results
4. American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety?
5. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
6. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
7. Air Filtration and Gas/Solid Separation Training by the American Filtration and Separations Society
8. Water Filtration and Liquid Separation Training by the American Filtration and Separations Society.
9. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
10. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
11. The American Society for Laser Medicine and Surgery Hosts Its 30th Annual Conference in Phoenix on April 14-18, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , 15 septembre 2014 La deuxième ... (IPAW) (semaine internationale sur la sensibilisation au ... Initiative conjointe de la Plasma Protein Therapeutics ... membres , l,IPAW vise à : ... de la collecte du plasma-aphérèse , Reconnaître ...
(Date:9/14/2014)... 2014 UMBC’s Biotechnology Graduate Programs’ ... October 21, 2014, from 12:00 to 1:00 p.m. EDT. ... innovative curriculum and practice-oriented instruction, designed for working professionals. ... help advance their career in the biotechnology industry. , ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers ...
(Date:9/12/2014)... a magnet using an electric field (magnetoelectric memory ... the next-generation technology for information processing and storage. ... effect, due to the coexistence of electric and ... of spontaneous electric and magnetic polarizations is rare ... of the MEM effect. This article briefly reviews ...
(Date:9/12/2014)... September 12, 2014 Today, “The University” ... Indiegogo. , The film, directed by former Charlie ... Shimon Peres, Ashton Kutcher, Will.i.Am, Michio Kaku, and others. ... there’s only one university in the world devoted to ... the lives of a billion people: Singularity University. Matt ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2
... SAN DIEGO , INDIANAPOLIS , and WALTHAM, Mass. , June ... Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ... of studies designed to test the superiority of BYDUREON™ (exenatide extended-release for injectable ... diabetes medications. , , , ...
... Inc. (Nasdaq: ISIS ) announced today that it will conduct the fourth ... Isis, development pipeline.  The last call of the series will focus on Isis, ... at 12:00 p.m. ET .  This call will be archived for a ... , , ...
... , June 15, 2010 Pieris AG,announced today the initiation ... PRS-050, an anti-VEGF Anticalin. The trial is an,open-label, dose-escalating evaluation of the ... in, Germany , the trial is underway and patients from the first ... , ...
Cached Biology Technology:DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 2DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 3DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 4DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 5DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 6DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 7DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 8DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 9Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 2Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 3Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound 2
(Date:9/15/2014)... 2014 Schizophrenia is generally considered to be a ... factors, both genetic and environmental, with other neurodevelopmental disorders ... path for brain development is determined by the combined ... wide range of environmental factors. , However, longitudinal brain ... required in order to map the disturbances in brain ...
(Date:9/15/2014)... tip the balance between ridding the body of a ... a report appearing in The Journal of ... viruses cause chronic infections in roughly three-quarters of infected ... diseases including cirrhosis and cancer. A few patients successfully ... CD8 + T cells. The protective effects of ...
(Date:9/15/2014)... available in German . ... the fossil energy carrier natural gas offers a variety ... Nevertheless, a consequent market penetration is still pending because ... Scientists of the Helmholtz Centre for Environ-mental Research (UFZ) ... Members of the IEA Task 37 (Energy from Biogas) ...
Breaking Biology News(10 mins):Brain Development in Schizophrenia Strays from the Normal Path 2The biomethane market needs clear frame conditions for further growth 2The biomethane market needs clear frame conditions for further growth 3
... multicenter clinical trial led by a researcher at the ... will evaluate a new approach to treat triple-negative breast ... common among African-Americans and young women. The study will ... reprogram tumor cells to express a protein called an ...
... Institution (WHOI) will lead the first international, multidisciplinary assessment ... the Pacific Ocean off the Fukushima nuclear power planta ... Foundation. "This project will address fundamental ... to the ocean, and in the process enhance international ...
... can sometimes be desirable such as in the taste ... rejection that can interfere with food selection, nutrition and therapeutic ... the Monell Center and Integral Molecular describe the discovery of ... subset of bitter taste receptors. "Bitter taste is ...
Cached Biology News:New clinical trial to test novel approach to treat triple-negative breast cancer 2New clinical trial to test novel approach to treat triple-negative breast cancer 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 2Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 4Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 5New bitter blocker discovered 2
...
Request Info...
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
... Synthetic peptide derived from the C-terminal ... Math-2. Specificity: Specific for the ... (positive controls: human U251 A172 IMR-32 ... rat brain homogenates)Storage: Store at -20C ...
Biology Products: